Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Hydromorphone for Chronic Pain
NCT01709721Phase 3Completed
- Sponsor
- Piramal
- Start
- Feb 2013
- Primary completion
- Feb 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of hydromorphone in chronic pain (2 arms), sponsored by Piramal. Primary endpoint: Proportion of Subjects Who Are Treatment Failures During the Double-blind Randomized Withdrawal Period at 5 weeks. Started Feb 2013; status: completed.
02
Drugs
hydromorphone
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT01709721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01709721.